The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents
Open accessAbstract
MET is a receptor tyrosine kinase known for its pleiotropic effects in tumorigenesis. Dysregulations of MET expression and/or signaling have been reported and determined to be associated with inferior outcomes in breast cancer patients rendering MET a versatile candidate for targeted therapeutic intervention. Crizotinib is a multi-targeted small-molecule kinase inhibitor for MET, ALK, and ROS1 kinases. This study evaluated the anti-proliferative, cytotoxic, anti-migratory, and anti-invasive effects of crizotinib in breast cancer cells in vitro. Cell viability was assessed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) colorimetric assay. In vitro wound-healing assay was used to examine the effect of crizotinib on breast cancer cell migration. The expressions of Ki-67, MET, and phospho-MET receptors were characterized using immunofluorescence staining. Results showed that crizotinib has significant anti-proliferative activity on all mammary tumor cells with IC 50 values of 5.16, 1.5, and 3.85 µM in MDA-MB-231, MCF-7, and SK-BR-3 cells, respectively. Crizotinib induced cytotoxic effects in all breast cancer cells examined. Combined treatment of small dose of crizotinib with paclitaxel or doxorubicin exhibited a highly synergistic inhibition of growth of MDA-MB-231 and MCF-7 cells with combination index values <1 while no significant effect was observed in SK-BR-3 cells compared with individual compounds. Treatment with crizotinib demonstrated a remarkable reduction in the expression of Ki-67 protein in all 3 tested cell lines. Crizotinib inhibited migration and invasion of MDA-MB-231 cells in a dose-dependent fashion. Crizotinib reduced MET receptor activation in MDA-MB-231 cells when treated at effective concentrations. In conclusion, crizotinib suppressed proliferation, migration, and invasion of breast cancer cells in vitro. The results of this study demonstrated that combined treatment of crizotinib with chemotherapeutic agents resulted in a synergistic growth inhibition of specific breast cancer cell lines. Keywords: crizotinib, breast cancer, MET receptor, chemotherapy, migration, invasion
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Crizotinib is a receptor tyrosine kinase inhibitor that inhibits the growth, migration, and invasion of breast cancer cells in preclinical studies43,44.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [43]
In the citing paper
“Crizotinib is a receptor tyrosine kinase inhibitor showing tumor-reducing effects in vitro and in vivo43,44. It is now in a phase 2 clinical trial for treating patients with TNBC (ClinicalTrials.gov Identifier: NCT03620643).”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Matteucci, E., Bendinelli, P., & Desiderio, M. A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp080 · Cited by 82
RetractedMolecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Cited by
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer
Raj, S., Kesari, K. K., Kumar, A., Rathi, B., Sharma, A., Gupta, P. K., Jha, S. K., Jha, N. K., Slama, P., Roychoudhury, S., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01503-1 · Cited by 162
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system
Huelse, J. M., Fridlyand, D. M., Earp, S. H., DeRyckere, D., & Graham, D. K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107577 · Cited by 107
ASGARD is a single-cell guided pipeline to aid repurposing of drugs
He, B., Xiao, Y., Liang, H., Huang, Q., Du, Y., Li, Y., Garmire, D., Sun, D., & Garmire, L. X. (2023) · Nature Communications · doi:10.1038/s41467-023-36637-3 · Cited by 57
Balsa, L. M., Ferraresi-Curotto, V., Lavecchia, M. J., Echeverría, G. A., Piro, O. E., García‐Tojal, J., Diez, R. P., González-Baró, A. C., & León, I. E. (2021) · Dalton Transactions · doi:10.1039/d1dt00869b · Cited by 61
Cationic liposomes co-deliver chemotherapeutics and siRNA for the treatment of breast cancer
Li, M., Li, S., Li, Y., Li, X., Yang, G., Li, M., Xie, Y., Su, W., Wu, J., Jia, L., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114198 · Cited by 55
Metadata
- Authors
- Ayoub, N., Al-Shami, K., Alqudah, M. A. Y., & Mhaidat, N.
- Affiliations
- Jordan University of Science and Technology (JO)
- Corresponding author
- Ayoub, Nehad
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-10
- Volume
- Volume 10
- Pages
- 4869-4883
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC5634371
- OpenAlex
- W2761975835
- Cited by
- 38
- References
- 73
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 7 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 5 · 2019: 1
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Jordan University of Science and Technology
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- crizotinib, MET receptor tyrosine kinase, breast cancer, kinase inhibitors, antiproliferative activity, cell migration, cell invasion, paclitaxel, doxorubicin, drug synergy, combination therapy, Ki-67, MDA-MB-231 cells, MCF-7 cells, SKBR3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.